The Company’s experienced management team have dedicated their initial focus to the development of a new class of small molecules, with specific antibacterial activity against susceptible and resistant bacteria. In providing a new class of drug to the field of antibacterial resistance, based on a truly novel mechanism of action, MGB Biopharma are unique, in that a truly new class and novel MoA was last seen in the year 2000.
There are many drugs used to treat bacterial infections, and generally they belong to classes which have been in use for several decades. Due to the rise in resistant strains of bacteria, several of these drugs are becoming less and less effective.
The Company’s progress has been rapid, and our lead drug candidate, MGB-BP-3, has recently initiated a Phase IIa clinical proof of concept study in CDAD patients. MGB-BP-3 is just the first in our new exciting class of anti-infectives.
MGB Biopharma commenced operations in 2010, and is funded by a syndicate of some of Scotland’s leading business angels, in co-operation with Scottish Enterprise.
MGB Biopharma believes that the antibiotic market for hospital acquired infection has changed dramatically, following major public health initiatives to promote the development of new antibacterials, such as the GAIN Act in the US.
This should provide companies with truly novel products, fast-track development and extended exclusivity periods. MGB Biopharma’s products could provide important and clinically meaningful benefits to an initially small, but significantly growing, patient population suffering from resistant bacterial infections. Resistant bacterial infections have been largely ignored by major pharmaceutical groups in recent years.
MGB Biopharma continues to work closely with the University of Strathclyde to develop the MGB pipeline. It also intends to work with other partners to maximise the value-creating opportunities from its broad platform and to ensure that the Company continues to deliver on its clinical and corporate objectives.